诱导免疫化疗在最初无法切除的食道状细胞癌中,比化疗产生更高的转化率和更好的整体生存率
Shujie Huang1, Sichao Wang2,3, Zhen Gao4
1Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Annals of surgical oncology
|May 25, 2024
概括
诱导免疫化疗 (iIC) 显著改善了不可切割的食道状细胞癌的手术转换和整体存活率 (OS). 这种方法提供了更好的治疗选择,增强了病理反应和患者的结果.
科学领域:
- 在瘤学瘤学.
- 手术瘤学手术瘤学
- 医学瘤学 医学瘤学
背景情况:
- 食道状细胞癌 (ESCC) 构成了重大挑战,特别是在最初无法切除的阶段.
- 标准诱导化疗 (IC) 在改善这些患者的治疗结果方面存在局限性.
研究的目的:
- 为了比较诱导免疫化疗 (iIC) 与诱导化疗 (iC) 在最初无法切除的ESCC患者的疗效.
- 评估iIC和iC对手术转换率和整体生存时间 (OS) 的影响.
主要方法:
- 这是一项多中心的回顾性队列研究,涉及来自四个大规模医疗机构的无法切除的ESCC患者.
- 主要终点包括转换手术率和OS,使用多变量考克斯回归和稳定治疗权重的逆概率进行分析.
主要成果:
- 诱导免疫化疗 (iIC) 与诱导化疗 (iC) (49.7%) 相比,显示了显著更高的转化手术率 (84.7%).
- 病理完整响应率在iIC (22.0%) 与iC (5.1%) 之间显著更高.
- 与iC (中位数为36.3个月) 相比,iIC (未达到) 显著改善了整体存活率 (OS),iIC和手术是OS的独立预后因素.
结论:
- 诱导免疫化疗 (iIC),然后进行转换手术,代表了最初无法切除的ESCC的优越治疗策略.
- 这种方法显著提高了病理反应率,并改善了无法切除的ESCC患者的整体存活率.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
21.3K
相关概念视频
Tumor Immunotherapy
515
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
515
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
